ProQR Therapeutics (PRQR) EBITDA Margin (2021 - 2026)
ProQR Therapeutics' EBITDA Margin came in at -92.65% for the quarter ended Jun 30, 2026, up 210.57 percentage points from -303.22% a year earlier and up 544.59 percentage points from the prior quarter.
ProQR Therapeutics (PRQR) EBITDA Margin (2021 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, ProQR Therapeutics reported EBITDA Margin of -218.85%, up 19.39 percentage points year-over-year; for the year ended Dec 31, 2025, it was -256.15%, down 109.57 percentage points from the prior year.
- EBITDA Margin carries a four-year change of +3854.79 percentage points (years ended Dec 2021 to Dec 2025).
- Going back by year, EBITDA Margin was -146.58% in the year ended Dec 31, 2024 (+303.93 pp), -450.51% in the year ended Dec 31, 2023 (+1292.34 pp), -1742.85% in the year ended Dec 31, 2022 (+2368.09 pp) and -4110.94% in the year ended Dec 31, 2021.
- The figure for the quarter ended Jun 30, 2026 represents the highest quarterly EBITDA Margin since the quarter ended Jun 30, 2024.
- Year-over-year, EBITDA Margin increased in three of the last eight quarters, with an average year-over-year change of -50.58 percentage points.
- The fastest year-over-year change in EBITDA Margin over five years came in the quarter ended Dec 31, 2022 (a gain of 5392.58 percentage points), and the weakest in the quarter ended Sep 30, 2022 (a drop of 753.08 percentage points).
- Business Quant data shows PRQR's EBITDA Margin at -637.24% (quarter ended Mar 31, 2026), -179.56% (quarter ended Dec 31, 2025) and -368.25% (quarter ended Sep 30, 2025) in the three quarters before the quarter ended Jun 30, 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | ProQR Therapeutics | 173.85 Mn | -289.75 Mn | - | -92.65% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -92.65% |
| Mar 31, 2026 | -637.24% |
| Dec 31, 2025 | -179.56% |
| Sep 30, 2025 | -368.25% |
| Jun 30, 2025 | -303.22% |
| Mar 31, 2025 | -224.34% |
| Dec 31, 2024 | -218.48% |
| Sep 30, 2024 | -208.90% |
| Jun 30, 2024 | -45.82% |
| Mar 31, 2024 | -165.93% |
| Dec 31, 2023 | -168.70% |
| Sep 30, 2023 | -492.63% |
| Jun 30, 2023 | -681.91% |
| Mar 31, 2023 | -1,349.62% |
| Dec 31, 2022 | -1,626.67% |
| Sep 30, 2022 | -2,360.07% |
| Jun 30, 2022 | -1,638.82% |
| Mar 31, 2022 | -1,457.88% |
| Dec 31, 2021 | -7,019.25% |
| Sep 30, 2021 | -1,607.00% |
ProQR Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=PRQR&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "PRQR", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=PRQR&period=max&api_key=YOUR_API_KEY");
const data = await res.json();